Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03727789 · ClinicalTrials.gov registry record · Phase 1
CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT03727789 is a Phase 1 study that was terminated before completion, run by Roswell Park Cancer Institute. The registered enrollment target is 7 participants.
The verdict
NCT03727789, a Phase 1 study, was terminated before completion, sponsored by Roswell Park Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This phase I trial studies best dose and side effects of CBL0137 in treating patients with extremity melanoma or sarcoma that has spread to other places in the body. Drugs, such as CBL0137, may work by binding to tumor cell deoxyribonucleic acid (DNA) to stop the cell from growing further.
Interventions
- DRUG FACT Complex-targeting Curaxin CBL0137
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2019-07-01 |
| Est. Completion | 2024-01-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03727789
The ClinicalTrials.gov registry entry for NCT03727789 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FACT Complex-targeting Curaxin CBL0137 is the first listed.
NCT03727789 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03727789 about?
NCT03727789 is a clinical study titled "CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma". This phase I trial studies best dose and side effects of CBL0137 in treating patients with extremity melanoma or sarcoma that has spread to other places in the body. Drugs, such as CBL0137, may work by binding to tumor cell deoxyribonucleic acid (DNA) to stop the cell from growing further.
What is the current status of trial NCT03727789?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2019-07-01. Estimated completion is 2024-01-16.
What interventions are being tested in trial NCT03727789?
The interventions under investigation include: FACT Complex-targeting Curaxin CBL0137 (DRUG).
Who is sponsoring clinical trial NCT03727789?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.